Overview

Delayed Tolerance Through Mixed Chimerism

Status:
Not yet recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
ITB-Med LLC
Ossium Health, Inc.
Treatments:
Cyclophosphamide
Fludarabine
Rituximab